{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:18:46Z","timestamp":1768472326108,"version":"3.49.0"},"reference-count":43,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bernola-Vallribera Foundation, Sant Josep 2018","award":["CIR2018\/036"],"award-info":[{"award-number":["CIR2018\/036"]}]},{"name":"Taul\u00ed Research and Innovation 2018","award":["CIR2018\/036"],"award-info":[{"award-number":["CIR2018\/036"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>A randomized, double-blind, and placebo-controlled study was conducted to assess the effect of dietary supplementation with high-rich docosahexaenoic acid (DHA) (Tridocosahexanoin-AOX\u00ae 70%) at 50 mg\/kg\/day in pediatric patients with cystic fibrosis (CF) as compared with placebo. The duration of supplementation was 12 months. A total of 22 patients were included, with 11 in the DHA group and 11 in the placebo group. The mean age was 11.7 years. The outcome variables were pulmonary function, exacerbations, sputum cellularity, inflammatory biomarkers in sputum and peripheral blood, and anthropometric variables. In the DHA group, there was a significant increase in FVC (p = 0.004) and FVE1 expressed in liters (p = 0.044) as compared with placebo, and a lower median number of exacerbations (1 vs. 2). Differences in sputum cellularity (predominantly neutrophilic), neutrophilic elastase, and sputum and serum concentrations of resolvin D1 (RvD1), interleukin (IL)-8 (IL-8), and tumor necrosis factor alpha (TNF-\u03b1) between the study groups were not found. Significant increases in weight and height were also observed among DHA-supplemented patients. The administration of the study product was safe and well tolerated. In summary, the use of a highly concentrated DHA supplement for 1 year as compared with placebo improved pulmonary function and reduced exacerbations in pediatric CF.<\/jats:p>","DOI":"10.3390\/nu16070970","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T14:17:34Z","timestamp":1711549054000},"page":"970","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of 1-Year Supplementation with High-Rich Docosahexaenoic Acid (DHA) on Clinical Variables and Inflammatory Biomarkers in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5245-9847","authenticated-orcid":false,"given":"Roser","family":"Ayats-Vidal","sequence":"first","affiliation":[{"name":"Pediatric Allergies, Immunology and Pneumology Unit, Pediatric Medicine Service, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Parc Taul\u00ed Hospital Universitari, Universitat Aut\u00f2noma de Barcelona, Parc Taul\u00ed 1, E-08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Bosque-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Pediatric Allergies, Immunology and Pneumology Unit, Pediatric Medicine Service, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Parc Taul\u00ed Hospital Universitari, Universitat Aut\u00f2noma de Barcelona, Parc Taul\u00ed 1, E-08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0418-9387","authenticated-orcid":false,"given":"Bego\u00f1a","family":"Cordobilla","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona, E-08028 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Asensio-De la Cruz","sequence":"additional","affiliation":[{"name":"Pediatric Allergies, Immunology and Pneumology Unit, Pediatric Medicine Service, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Parc Taul\u00ed Hospital Universitari, Universitat Aut\u00f2noma de Barcelona, Parc Taul\u00ed 1, E-08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Pediatric Allergies, Immunology and Pneumology Unit, Pediatric Medicine Service, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Parc Taul\u00ed Hospital Universitari, Universitat Aut\u00f2noma de Barcelona, Parc Taul\u00ed 1, E-08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Loureda-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Pediatric Allergies, Immunology and Pneumology Unit, Pediatric Medicine Service, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Parc Taul\u00ed Hospital Universitari, Universitat Aut\u00f2noma de Barcelona, Parc Taul\u00ed 1, E-08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Fern\u00e1ndez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Physical Medicine and Rehabilitation Service, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Parc Taul\u00ed Hospital Universitari, Universitat Aut\u00f2noma de Barcelona, Parc Taul\u00ed 1, E-08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Robert-Barriocanal","sequence":"additional","affiliation":[{"name":"Physical Medicine and Rehabilitation Service, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Parc Taul\u00ed Hospital Universitari, Universitat Aut\u00f2noma de Barcelona, Parc Taul\u00ed 1, E-08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Valiente-Planas","sequence":"additional","affiliation":[{"name":"Physical Medicine and Rehabilitation Service, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Parc Taul\u00ed Hospital Universitari, Universitat Aut\u00f2noma de Barcelona, Parc Taul\u00ed 1, E-08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6356-0836","authenticated-orcid":false,"given":"Joan Carles","family":"Domingo","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona, E-08028 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Shrestha, N., McCarron, A., Rout-Pitt, N., Donnelley, M., Parsons, D.W., and Hryciw, D.H. (2022). Essential fatty acid deficiency in cystic fibrosis disease progression: Role of genotype and sex. Nutrients, 14.","DOI":"10.3390\/nu14214666"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102156","DOI":"10.1016\/j.plefa.2020.102156","article-title":"Abnormal n-6 fatty acid metabolism in cystic fibrosis contributes to pulmonary symptoms","volume":"160","author":"Wheelock","year":"2020","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"ref_3","first-page":"548","article-title":"Review of rapid advances in cystic fibrosis","volume":"117","author":"Link","year":"2020","journal-title":"Mo. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1203\/PDR.0b013e3181b4e8d3","article-title":"Persistence of essential fatty acid deficiency in cystic fibrosis despite nutritional therapy","volume":"66","author":"Prieto","year":"2009","journal-title":"Pediatr. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"16083","DOI":"10.3390\/ijms150916083","article-title":"Abnormal unsaturated fatty acid metabolism in cystic fibrosis: Biochemical mechanisms and clinical implications","volume":"15","author":"Seegmiller","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcf.2004.11.001","article-title":"Docosahexaenoic acid trials in cystic fibrosis: A review of the rationale behind the clinical trials","volume":"4","author":"Robberecht","year":"2005","journal-title":"J. Cyst. Fibros."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.plefa.2010.07.002","article-title":"Fatty acid metabolism in cystic fibrosis","volume":"83","author":"Strandvik","year":"2010","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1203\/00006450-198501000-00028","article-title":"Fatty acid abnormalities in cystic fibrosis","volume":"19","author":"Farrell","year":"1985","journal-title":"Pediatr. Res."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Vandebrouck, C., and Ferreira, T. (2020). Glued in lipids: Lipointoxica-tion in cystic fibrosis. EBioMedicine, 61.","DOI":"10.1016\/j.ebiom.2020.103038"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nri.2015.4","article-title":"Specialized pro-resolving mediators: Endogenous regulators of infection and inflammation","volume":"16","author":"Basil","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.arbres.2009.11.001","article-title":"Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis","volume":"46","author":"Olveira","year":"2010","journal-title":"Arch. Bronconeumol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.plefa.2016.03.014","article-title":"The clinical benefits of long-term supplementation with omega-3 fatty acids in cystic fibrosis patients\u2014A pilot study","volume":"108","author":"Hanssens","year":"2016","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/014860710302700152","article-title":"Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis","volume":"27","author":"Raia","year":"2003","journal-title":"JPEN J. Parenter. Enteral. Nutr."},{"key":"ref_14","first-page":"CD002201","article-title":"Omega-3 fatty acids for cystic fibrosis","volume":"2016","author":"Oliver","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_15","first-page":"CD002201","article-title":"Omega-3 fatty acid supplementation for cystic fibrosis","volume":"4","author":"Watson","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ayats-Vidal, R., Bosque-Garc\u00eda, M., Cordobilla, B., Asensio-De la Cruz, O., Garc\u00eda-Gonz\u00e1lez, M., Castro-Marrero, J., L\u00f3pez-Rico, I., and Domingo, J.C. (2023). Changes of erythrocyte fatty acids after supplementation with highly concentrated docosahexaenoic acid (DHA) in pediatric cystic fibrosis: A randomized double-blind controlled trial. J. Clin. Med., 12.","DOI":"10.3390\/jcm12113704"},{"key":"ref_17","unstructured":"Brudy Technology SL (2014). Use of DHA for Treating a Pathology Associated with Cellular Oxidative Damage. (EP 1962825 B1), European Patent."},{"key":"ref_18","first-page":"5932","article-title":"Docosahexaenoic acid improves endogenous antioxidant defense in ARPE-19 cells","volume":"49","author":"Gasso","year":"2008","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nut.2005.05.006","article-title":"Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: A randomized, controlled study","volume":"22","author":"Powers","year":"2006","journal-title":"Nutrition"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jnutbio.2018.09.026","article-title":"A comprehensive evaluation of omega-3 fatty acid supplementation in cystic fibrosis patients using lipidomics","volume":"63","author":"Pastor","year":"2019","journal-title":"J. Nutr. Biochem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"102186","DOI":"10.1016\/j.plefa.2020.102186","article-title":"Long-term docosahexaenoic acid (DHA) supplementation in cystic fibrosis patients: A randomized, multi-center, double-blind, placebo-controlled trial","volume":"162","author":"Garriga","year":"2020","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0300-2896(01)75069-7","article-title":"Sputum induction for the diagnosis and monitoring of respiratory disease","volume":"37","author":"Belda","year":"2001","journal-title":"Arch. Bronconeumol."},{"key":"ref_23","unstructured":"Belda, J., Giner, J., Torrej\u00f3n, M., and Casan, P. (2004). Manual SEPAR de Procedimientos. Pruebas Para el Estudio de la Inflaci\u00f3n de las V\u00edas A\u00e9reas, Permanyer."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_25","first-page":"388","article-title":"Spirometry. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)","volume":"49","author":"Calle","year":"2013","journal-title":"Arch. Bronconeumol."},{"key":"ref_26","first-page":"217","article-title":"Spirometric reference values from a Mediterranean population","volume":"22","author":"Roca","year":"1986","journal-title":"Bull. Eur. Physiopathol. Respir."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1164\/rccm.201203-0507OC","article-title":"Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis","volume":"186","author":"Sagel","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/ppul.26491","article-title":"Impact of omega-3 supplementation on children and adolescents patients with cystic fibrosis: A systematic review and meta-analysis of randomized-controlled trials","volume":"58","author":"Sohouli","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"ref_29","first-page":"389","article-title":"Clinical effects of diet supplementation with DHA in pediatric patients suffering from cystic fibrosis","volume":"65","author":"Leggieri","year":"2013","journal-title":"Minerva Pediatr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0140-6736(93)91594-C","article-title":"Eicosapentaenoic acid in cystic fibrosis: Evidence of a pathogenetic role for leukotriene B4","volume":"342","author":"Lawrence","year":"1993","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.plefa.2012.10.002","article-title":"A randomized placebo-controlled study on high-dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis","volume":"88","author":"Alicandro","year":"2013","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.plefa.2007.12.005","article-title":"Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients","volume":"78","author":"Devos","year":"2008","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1515\/hsz-2015-0271","article-title":"Neutrophils in cystic fibrosis","volume":"397","author":"Laval","year":"2016","journal-title":"Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3389\/fphar.2019.00938","article-title":"Arachidonic acid and docosahexaenoic acid metabolites in the airways of adults with cystic fibrosis: Effect of docosahexaenoic acid supplementation","volume":"10","author":"Teopompi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Eickmeier, O., Fussbroich, D., Mueller, K., Serve, F., Smaczny, C., Zielen, S., and Schubert, R. (2017). Pro-resolving lipid mediator resolvin D1 serves as a marker of lung disease in cystic fibrosis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0171249"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3389\/fphar.2020.01290","article-title":"The role of specialized pro-resolving mediators in cystic fibrosis airways disease","volume":"11","author":"Briottet","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3389\/fphar.2019.00252","article-title":"Roles, actions, and therapeutic potential of specialized pro-resolving lipid mediators for the treatment of inflammation in cystic fibrosis","volume":"10","author":"Recchiuti","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0002-9440(10)65633-7","article-title":"Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro","volume":"153","author":"Tabary","year":"1998","journal-title":"Am. J. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2174\/1389450117666151209120516","article-title":"Dysregulated chemokine signaling in cystic fibrosis lung disease: A potential therapeutic target","volume":"17","author":"Guan","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/00365540050164263","article-title":"TNF-alpha and IL-8 in consecutive sputum samples from cystic fibrosis patients during antibiotic treatment","volume":"32","author":"Karpati","year":"2000","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejphar.2015.11.001","article-title":"DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation","volume":"785","author":"Duvall","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2174\/1568026611109060629","article-title":"Novel anti-inflammatory--pro-resolving mediators and their receptors","volume":"11","author":"Serhan","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1146\/annurev-physiol-021113-170408","article-title":"Resolution of acute inflammation in the lung","volume":"76","author":"Levy","year":"2014","journal-title":"Annu. Rev. Physiol."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/16\/7\/970\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:19:36Z","timestamp":1760105976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/16\/7\/970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["nu16070970"],"URL":"https:\/\/doi.org\/10.3390\/nu16070970","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,27]]}}}